← board
SILO
distress 7/10 · high distress / dilution risk$4.61-2%today-62% from 52w high
Lead: PTSD
Revenue
pre-revenue
Liquidity
$6M
Runway
1.3 yrs
Shares 1y
+73%
Price & events
-16.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.1%
1D
-5.4%
1W
-23.4%
1M
-46.1%
3M
-16.7%
6M
-51.4%
1Y
-87.0%
2Y
-96.0%
5Y
-98.2%
All
Overview
- Market Cap
- $74.99M
- Volume
- 12.40K
- 52 Week Range
- $4.21 – $12.22
- Total Shares
- 16.27M
- Float Shares
- 1.07M
- Short %
- 1.78%
- % Held by Insiders
- 16.41%
- % Held by Institutions
- 11.11%
- RVOL
- 0.04x
- Beta
- 0.75
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 10
- 2025 datareadoutPhase 1SPU-16 · Data readout for CNS homing peptideSEC 8-K
- 2025 datareadoutPhase 1SPC-14 · Data readout for Alzheimer's programSEC 8-K
- upon IND approval in 2025trial initiationsecondaryPhase 1SPC-15 · Phase 1 clinical trial to follow IND approvalSEC 8-K
- IND expected in 2025regulatory submissionFiled (NDA/BLA)SPC-15 · IND submission for intranasal PTSD treatmentSEC 8-K
- October 1, 2025trial initiationsecondaryClosing of the offeringSEC 8-K
- September 30, 2025conferencedata presentationsecondaryPress release announcing pricing of offeringSEC 8-K
- early 2025readoutSP-26 · Results from first animal study evaluating dosage, time release, and absorptionSEC 8-K
- March 2025 datareadoutPhase 1SP-26 · Data readout for ketamine implantSEC 8-K
- 2025-03-04partnershipPatent US 12,239,614 granted for exclusively licensed pharmacological prophylactics against stress-induced affective disorders in females from Columbia University.SEC 8-K
- 2024-09-01fda agreementSPC-15 · Pre-IND meeting with FDA in September 2024 to align on 505(b)(2) development planSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Recent news
- 2026-07-22AlgoSec Horizon A33.30 Eliminates Security Silos, Accelerates Application Delivery, Automates Policy Management and Continuously Reduces Cyber Risk - Business Wire
- 2026-07-22AlgoSec Horizon A33.30 eliminates security silos, - GlobeNewswire
- 2026-07-21Silo Pharma Advances AI Agent Platform Toward Commercial Launch And Progresses Lead PTSD Drug Program SPC-15 - marketscreener.com
- 2026-07-21Silo Season 3 Episode 4 Preview: What Real Nanotechnology and Memory Chemistry Actually Say - Tech Times
- 2026-07-21Silo Pharma to launch AI platform and advances PTSD drug SPC-15 with FDA steps ahead - Pluang
- 2026-07-21Silo Pharma Advances QwikAgents Commercial Launch and SPC-15 Development - Quiver Quantitative
- 2026-07-21Silo Pharma expects its PTSD nasal-spray study to finish in 60 days - Stock Titan
- 2026-07-21Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.